Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting® 2026, to be held from November 5-9, 2026, in Denver, Colorado.
Covered in this story
Call it yourself
No calls on $IVA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Inventiva →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.